Evidence map›Paper›PMID 37894422›Full record

ArticleCancers2023

Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study.

Kriti Gera, Doga Kahramangil, Graeme A Fenton, Daniela Martir, Diana N Rodriguez, Zohaib Ijaz, Rick Y Lin, Sherise C Rogers, Brian H Ramnaraign, Thomas J George and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Research progress on prognostic factors of gallbladder carcinoma.Journal of cancer research and clinical oncology · 2024
    Review
  4. Risk Factors and Prognostic Factors in GBC.Journal of clinical medicine · 2024
    Review
  5. Article
  6. Article
  7. Exosomes: a promising avenue for cancer diagnosis beyond treatment.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kriti GeraDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Doga KahramangilDivision of Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Graeme A FentonUniversity of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0002-6418-1221
Daniela MartirDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Diana N RodriguezDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Zohaib IjazDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Rick Y LinDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0001-6226-0375
Sherise C RogersDivision of Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Brian H RamnaraignDivision of Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0003-4051-4551
Thomas J GeorgeDivision of Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0002-6249-9180
Young-Rock HongUniversity of Florida Health Cancer Center, Gainesville, FL 32610, USA.ORCID 0000-0002-0366-5687
Steven J HughesDivision of Surgical Oncology, Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Ibrahim NassourDivision of Surgical Oncology, Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0002-9845-1074
Ilyas SahinDivision of Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0003-2070-9319
University of Florida · USUniversity of Florida Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGallbladder carcinoma (GBC) is a rare, aggressive malignancy comprising 0.5% of gastrointestinal cancers. It has poor survival outcomes due to its insidious onset, lack of standardized screening, and limited therapies. Advanced-stage diagnosis with liver, lymph node, and peritoneal metastasis is common, while bone metastasis is rare. The knowledge on bone metastasis in GBC is limited to case reports and small series, and its clinical significance is largely unexplored.

methodsThe study extracted the demographic and clinical variables of patients with metastatic (M1) gallbladder adenocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) database between 2011 and 2020. Descriptive statistics were used to analyze the demographic characteristics. The multivariate Cox regression analysis was used to calculate the hazard ratio. The overall survival (OS) was assessed using the Kaplan-Meier method, and the log-rank test was utilized to compare the survival between the groups.

resultsA total of 2724 patients were included in the study. A total of 69% of the patients were female, and the median age was 68 (range 24-90+). A total of 7.4% of the patients had bone metastasis on diagnosis. The multivariate Cox analysis identified bone metastasis as an independent mortality risk factor in metastatic GBC (HR 1.50,

conclusionsOur findings suggest that the presence of bone metastasis in gallbladder adenocarcinoma is an independent prognostic factor associated with unfavorable survival outcomes in the younger age group (18-74 years). However, in the older age group (75+ years), the presence of bone metastasis did not impact the survival. Treatment with chemotherapy was associated with extended survival in all patients. Thus, early detection and aggressive management of bone metastasis, including the consideration of chemotherapy, may be crucial in improving the OS and quality of life for individuals with gallbladder adenocarcinoma.

Indexed as

biliary tract cancerbone metastasischolangiocarcinoma

Identifiers

PMID37894422
PMCPMC10605374
OpenAlexW4387775574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.